A Snapshot Of Neglected Disease Drug Development: Dengue Fever
This article was originally published in PharmAsia News
Neglected diseases are gaining a higher profile in Big Pharma drug development programs. Research on a vaccine for dengue fever has been ongoing for decades, and a few candidates could finally be nearing late-stage trials.
You may also be interested in...
Novartis Head of Corporate Research And Chairman, Novartis Institute For Tropical Diseases, Paul Herrling On The Need For Government Funding For Neglected Diseases: An Interview With PharmAsia News
Paul Herrling, Head of Corporate Research at Novartis and Chairman of the Novartis Institute For Tropical Diseases, Singapore spends a week each month in Singapore and for the rest he fulfills his other global commitments. Herrling sat down with PharmAsia News in Singapore to discuss research initiatives for neglected diseases and controversies revolving around his proposal for a fund to research neglected diseases by multiple governments.
Regulators in Southeast Asia are working to tighten bribery and corruption enforcement as part of a broader push ahead of an Association of Southeast Asian Nations trade pact in 2015 for greater transparency in pharmaceuticals.
The first commercial implant for St. Jude’s Allure Quadra in Hong Kong is a sign for optimism for its pacemaker business after last year’s disappointments in Japan.